Maze Therapeutics reports Q2 2025 net loss of $33.7M, cash $264.5M

Maze Therapeutics, Inc.

2025-Q2 EPS reported -$1.83 vs consensus -$0.87 ▼ miss (-109.6%)

Net loss of $33.7M in Q2 2025 vs net income of $139.1M in Q2 2024 (prior year had $165M license revenue).
Cash and cash equivalents $264.5M as of June 30, 2025 vs $196.8M at Dec 31, 2024; runway into H2 2027.
R&D expenses increased to $28.1M in Q2 2025 from $19.5M in Q2 2024 due to clinical trial costs.
MZE782 Phase 1 proof-of-mechanism data expected Q3 2025; MZE829 Phase 2 HORIZON data expected Q1 2026.
No license revenue recognized in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.